NBTX Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.

Nanobiotix SA has a consensus price target of $14.75, signalling downside risk potential of -30.73%. On the other hand DBV Technologies SA has an analysts' consensus of $40.03 which suggests that it could grow by 109.38%. Given that DBV Technologies SA has higher upside potential than Nanobiotix SA, analysts believe DBV Technologies SA is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Nanobiotix SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 31.60x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.

Nanobiotix SA has a consensus price target of $14.75, signalling downside risk potential of -30.73%. On the other hand Innate Pharma SA has an analysts' consensus of $5.15 which suggests that it could grow by 203.18%. Given that Innate Pharma SA has higher upside potential than Nanobiotix SA, analysts believe Innate Pharma SA is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.148%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 31.60x versus 21.95x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat Inventiva SA's return on equity of --.

Nanobiotix SA has a consensus price target of $14.75, signalling downside risk potential of -30.73%. On the other hand Inventiva SA has an analysts' consensus of $15.33 which suggests that it could grow by 245.35%. Given that Inventiva SA has higher upside potential than Nanobiotix SA, analysts believe Inventiva SA is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.433%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than Inventiva SA's net income of --. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 31.60x versus 25.85x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -- compared to Nanobiotix SA's net margin of 21.47%. Nanobiotix SA's return on equity of -- beat Johnson & Johnson's return on equity of 33.27%.

Nanobiotix SA has a consensus price target of $14.75, signalling downside risk potential of -30.73%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.73%. Given that Johnson & Johnson has higher upside potential than Nanobiotix SA, analysts believe Johnson & Johnson is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.47% to investors and pays a quarterly dividend of $1.30 per share. Nanobiotix SA pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Nanobiotix SA quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24B. Nanobiotix SA's net income of -- is lower than Johnson & Johnson's net income of $5.2B. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 20.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 31.60x versus 5.47x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.